Details

Autor(en) / Beteiligte

• Pitt, Bertram
• Pfeffer, Marc A
• Assmann, Susan F
• Boineau, Robin
• Anand, Inder S
• Claggett, Brian
• Clausell, Nadine
• Desai, Akshay S
• Diaz, Rafael
• Fleg, Jerome L
• Gordeev, Ivan
• Harty, Brian
• Heitner, John F
• Kenwood, Christopher T
• Lewis, Eldrin F
• O'Meara, Eileen
• Probstfield, Jeffrey L
• Shaburishvili, Tamaz
• Shah, Sanjiv J
• Solomon, Scott D
• Sweitzer, Nancy K
• Yang, Song
• McKinlay, Sonja M

Titel

Spironolactone for Heart Failure with Preserved Ejection Fraction

Ist Teil von

• The New England journal of medicine, 2014-04, Vol.370 (15), p.1383-1392

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial, 3445 patients with heart failure and a preserved ejection fraction were assigned to spironolactone or placebo. At a mean of 3.3 years, there was no significant difference in death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure. Many patients with heart failure have a normal or near-normal left ventricular ejection fraction. 1 – 4 Such patients share common signs and symptoms, as well as an impaired quality of life and a poor prognosis, with patients who have heart failure and a reduced ejection fraction. 5 – 8 However, the benefit of most medical therapies for heart failure is limited to those with a reduced ejection fraction, generally 40% or less. 1 , 2 , 9 The lack of favorable evidence from clinical-outcome trials involving patients with heart failure and a preserved left ventricular ejection fraction is reflected in current guidelines, which offer no specific . . .